Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease

Table 2 Clinical features of the cohort of patients with inflammatory bowel disease and cancer diagnosis n (%)

Features	Value
Disease extension (UC)1
Proctitis	1 (11.1)
Left-sided colitis	4 (44.45)
Pancolitis	4 (44.45)
Age at diagnosis (CD)1
A2 17-40	8 (88.89)
A3 > 40	1 (11.11)
Disease location (CD)1
L1 ileal	4 (44.45)
L2 colic	2 (22.22)
L3 ileocolic	2 (22.22)
L3 + L4 upper gastrointestinal tract	1 (11.11)
Behaviour (CD)1
B1 non-stricturing non-penetrating	7 (77.78)
B2 stricturing	1 (11.11)
B1 + perianal disease	1 (11.11)
Treatment at time of cancer diagnosis
Aminosalicylates	10 (55.56)
Thiopurines	6 (33.34)
Anti-TNF-α drugs	1 (5.55)
Nonspecific inflammatory bowel disease treatment	1 (5.55)
Immunosuppressive or biological treatment previous cancer diagnosis
Thiopurines	1 (5.55)
Anti-TNF-α drugs	1 (5.55)

¹In accordance with the Montreal classification. CD: Crohn's disease; UC: Ulcerative colitis; TNF-α: Tumor necrosis factor α.